Multiple Myeloma, Phase I
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Volunteers
Health Professionals
What is the purpose of this trial?
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Parts B and C), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Alfredo Axtmayer
- Elan Gorshein, DO, JD, MPH
- Erica Stevens
- Iris Isufi, MD
- Kristen Hoxie
- Lourdes Mendez, MD, PhD
- Natalia Neparidze, MD
- Nikolai Podoltsev, MD, PhD
- Rory Shallis, MD
- Sabrina Browning, MD
- Sara Anastasio, RN
- Scott Huntington, MD, MPH, MSc
- Shalin Kothari, MD
- Stephanie Halene, MD, Dr Med
- Stuart Seropian, MD
- Tara Anderson
- Tarsheen Sethi, MD, MSc
- Terri Parker, MD
- Thomas Prebet, MD, PhD
- Last Updated04/12/2024
- Study HIC#2000025979